investors/
44 pages · Updated July 26, 2026
Pages
- Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.
- Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.
- rss
- rss
- rss
- Corporate Governance :: Carrick Therapeutics, Inc.
- Board of Directors :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts :: Carrick Therapeutics, Inc.
- Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.
- Management Team :: Carrick Therapeutics, Inc.
- rss
- Press Releases :: Carrick Therapeutics, Inc.
- Board Diversity :: Carrick Therapeutics, Inc.
- rss
- rss
- Whistleblower Policy :: Carrick Therapeutics, Inc.
- Section 16 Filings :: Carrick Therapeutics, Inc.
- Governance Documents :: Carrick Therapeutics, Inc.
- Board Committees :: Carrick Therapeutics, Inc.
- ESG :: Carrick Therapeutics, Inc.
- Annual Reports :: Carrick Therapeutics, Inc.
- Quarterly Reports :: Carrick Therapeutics, Inc.
- SEC Filings :: Carrick Therapeutics, Inc.
- All SEC Filings :: Carrick Therapeutics, Inc.
- Charts :: Carrick Therapeutics, Inc.
- Historical Data :: Carrick Therapeutics, Inc.
- Quote :: Carrick Therapeutics, Inc.
- Contacts :: Carrick Therapeutics, Inc.
- stock-data
- Company Information :: Carrick Therapeutics, Inc.
- Financial Results :: Carrick Therapeutics, Inc.
- Financial Information :: Carrick Therapeutics, Inc.
- FAQ :: Carrick Therapeutics, Inc.
- IR Calendar :: Carrick Therapeutics, Inc.
- News & Events :: Carrick Therapeutics, Inc.
- Annual Reports & Proxy Statements :: Carrick Therapeutics, Inc.
- Presentations :: Carrick Therapeutics, Inc.
- Email Alerts :: Carrick Therapeutics, Inc.